Literature DB >> 19504718

Analyzing antibody activity in IgA nephropathy.

Richard J Glassock1.   

Abstract

IgA nephropathy is a chronic kidney disease defined by deposition of IgA in the glomeruli. An abnormality in the glycosylation of the hinge region of the IgA1 isotype of IgA is fundamental to the origins of this very common form of glomerulonephritis. In this issue of the JCI, Suzuki and coworkers describe the characteristics of IgG autoantibodies to the abnormally glycosylated IgA1 secreted by immortalized B cells derived from patients with sporadic forms of IgA nephropathy (see the related article beginning on page 1668). These IgG autoantibodies displayed remarkably restricted heterogeneity. These observations offer new insights into disease pathogenesis and may lead to new methods of diagnosis, monitoring, and therapy for patients with IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504718      PMCID: PMC2689125          DOI: 10.1172/jci39189

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Impairment of jacalin binding to serum IgA in IgA nephropathy.

Authors:  P M Andre; P Le Pogamp; D Chevet
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

2.  [Intercapillary deposits of IgA-IgG].

Authors:  J Berger; N Hinglais
Journal:  J Urol Nephrol (Paris)       Date:  1968-09

Review 3.  The commonest glomerulonephritis in the world: IgA nephropathy.

Authors:  G D'Amico
Journal:  Q J Med       Date:  1987-09

4.  O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role.

Authors:  Y Hiki; A Horii; H Iwase; A Tanaka; Y Toda; K Hotta; Y Kobayashi
Journal:  Contrib Nephrol       Date:  1995       Impact factor: 1.580

5.  Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy.

Authors:  J Mestecky; M Tomana; P A Crowley-Nowick; Z Moldoveanu; B A Julian; S Jackson
Journal:  Contrib Nephrol       Date:  1993       Impact factor: 1.580

6.  Glomerular and serum immunoglobulin G subclasses in IgA nephropathy.

Authors:  P Aucouturier; R C Monteiro; L H Noël; J L Preud'homme; P Lesavre
Journal:  Clin Immunol Immunopathol       Date:  1989-06

7.  Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins.

Authors:  T Kokubo; Y Hiki; H Iwase; A Tanaka; K Toma; K Hotta; Y Kobayashi
Journal:  J Am Soc Nephrol       Date:  1998-11       Impact factor: 10.121

8.  Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients.

Authors:  G D'Amico; E Imbasciati; G Barbiano Di Belgioioso; S Bertoli; G Fogazzi; F Ferrario; G Fellin; A Ragni; G Colasanti; L Minetti
Journal:  Medicine (Baltimore)       Date:  1985-01       Impact factor: 1.889

9.  Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.

Authors:  A C Allen; S J Harper; J Feehally
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

10.  Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus.

Authors:  M E Conley; M D Cooper; A F Michael
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

View more
  10 in total

Review 1.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

2.  Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy.

Authors:  Dong Ho Shin; Beom Jin Lim; In Mi Han; Seung Gyu Han; Young Eun Kwon; Kyoung Sook Park; Mi Jung Lee; Hyung Jung Oh; Jung Tak Park; Seung Hyeok Han; Shin-Wook Kang; Tae-Hyun Yoo
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

3.  Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.

Authors:  Feng Ma; Xiaoxia Yang; Meilan Zhou; Ming Bai; Lijuan Zhao; Li Li; Ruijuan Dong; Chunmei Liu; Rong Li; Shiren Sun
Journal:  J Nephrol       Date:  2020-05-23       Impact factor: 3.902

4.  Update on immunoglobulin A nephropathy, Part I: Pathophysiology.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2015-09-06

Review 5.  Pathological role of tonsillar B cells in IgA nephropathy.

Authors:  Yusuke Suzuki; Hitoshi Suzuki; Junichiro Nakata; Daisuke Sato; Tadahiro Kajiyama; Tomonari Watanabe; Yasuhiko Tomino
Journal:  Clin Dev Immunol       Date:  2011-07-18

6.  Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy.

Authors:  Tadahiro Kajiyama; Yusuke Suzuki; Masao Kihara; Hitoshi Suzuki; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Clin Dev Immunol       Date:  2011-06-30

Review 7.  Genetics and immunopathogenesis of IgA nephropathy.

Authors:  Hsin-Hui Yu; Kuan-Hua Chu; Yao-Hsu Yang; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 10.817

8.  Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries.

Authors:  Yuko Makita; Hitoshi Suzuki; Daisuke Nakano; Hiroyuki Yanagawa; Toshiki Kano; Jan Novak; Akira Nishiyama; Yusuke Suzuki
Journal:  Nephrol Dial Transplant       Date:  2022-08-22       Impact factor: 7.186

9.  TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.

Authors:  Yuko Makita; Hitoshi Suzuki; Toshiki Kano; Akiko Takahata; Bruce A Julian; Jan Novak; Yusuke Suzuki
Journal:  Kidney Int       Date:  2019-09-05       Impact factor: 10.612

10.  Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy.

Authors:  Masashi Aizawa; Yusuke Suzuki; Hitoshi Suzuki; Huihua Pang; Masao Kihara; Junichiro Nakata; Kenji Yamaji; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.